U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106762) titled 'Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy' on Aug. 05.
Brief Summary: A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Study Start Date: Oct. 22
Study Type: INTERVENTIONAL
Condition:
Urothelial Cancer
Intervention:
DRUG: Iza-bren
Specified dose on specified days
DRUG: Cisplatin
Specified dose on specified days
DRUG: Gemcitabine
Specified dose on specified days
DRUG: Carboplatin
Specified dose on sp...